PCVX Stock Nearing 52-Week High

Rocketing to a price of $78.89 during today's afternoon trading session, shares of Vaxcyte are still -23.51% below their average target price of $103.14. Could there be more upside potential for the stock? Analysts are giving PCVX an average rating of buy and target prices ranging from $95.0 to $113.0 dollars per share.

For the greater market's outlook on the stock, we can use Vaxcyte's short interest as a proxy. The short interest represents the proportion of the float's shares that are tied to short positions, meaning that the investor believes the stock will decline in the future. Here, the stock's short interest is 10.3% which means the outlook is split.

Short selling involves borrowing shares and then selling them at current market prices. In the successful version of the strategy, the shares are purchased at a lower price at some time in the future. The investor then returns the shares to the lender, and keeps the profit made on the sell/buy transaction.

Another way to gauge the sentiment on Vaxcyte is to look at the percentage of institutions that are invested in the stock. In this case, 112.2% of the shares are held by pension, mutual, and hedge funds, which shows that these institutions probably have strong confidence in the stock.

If institutions are invested in a particular stock, it shows in most cases that they have performed quality research and concluded that it is a good investment. In some cases, however, increases in institutional ownership could be a sign of a takeover attempt or proxy fight, which can actually injure share prices. Also, institutions are not infallible, and can certainly make miscalculations -- often with spectacular results.

In conclusion, we see mixed market sentiment regarding Vaxcyte because of an analyst consensus of strong upside potential, a buy rating, an above average percentage of its shares sold short, and a significant number of institutional investors. At Market Inference, we believe that any investment decision should be preceded by an in-depth analysis of the company's fundamental values and a comparison with similar stocks.

Here's a snapshot of some important facts to keep in mind about PCVX:

  • The stock has trailing 12 month earnings per share (EPS) of $-4.29

  • Vaxcyte has a trailing 12 month Price to Earnings (P/E) ratio of -18.4 compared to the S&P 500 average of 27.65

  • The company has a Price to Book (P/B) ratio of 4.32 in contrast to the S&P 500's average ratio of 4.59

  • Vaxcyte is a Health Care company, and the sector average P/E and P/B ratios are 27.53 and 3.61 respectively

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.